VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment

Cancer Research

Volumn 71, Issue 1, 2011, Pages 143-153

  Nagengast, Wouter B ^a   Lub de Hooge, Marjolijn N ^a   Oosting, Sjoukje F ^a   Den Dunnen, Wilfred F A ^a   Warnders, Frank Jan ^a   Brouwers, Adrienne H ^a   De Jong, Johan R ^a   Price, Patricia M ^b   Hollema, Harry ^a   Hospers, Geke A P ^a   Elsinga, Philip H ^a   Hesselink, Jan Willem ^a   Gietema, Jourik A ^a   De Vries, Elisabeth G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; RANIBIZUMAB ZR 89; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; WATER O 15; ZIRCONIUM;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER GROWTH; COLON CANCER; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MOUSE; NONHUMAN; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERIAL ANALYSIS OF GENE EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; FLUORODEOXYGLUCOSE F18; HUMANS; INDOLES; MALE; MICE; MICE, NUDE; POSITRON-EMISSION TOMOGRAPHY; PYRROLES; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78651397295     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1088     Document Type: Article

References (38)

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
2. Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007;18Suppl 10:x3-10.
3. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
4. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
5. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993;4:1317-26.
6. Nagengast WB, De Vries EG, Hospers GA, de Mulder, Jr. NH, Hollema H, Brouwers AH, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007;48: 1313-9.
7. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
8. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70.
9. De Vries EG, Meijer C, Timmer-Bosscha H, Berendsen HH, de LL, Scheper RJ, Mulder NH, et al. Resistance mechanisms in three human small cell lung cancer cell lines established from one patient during clinical follow-up. Cancer Res 1989;49:4175-8.
10. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986;27:235-8.
11. Verel I, Visser GW, Boerman OC, van Eerd JE, Finn R, Boellaard R, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm 2003;18:655-61.
12. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2003;2:131-7.
13. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 2007;104:17069-74.
14. Keyes KA, Mann L, Teicher B, Alvarez E. Site-dependent angiogenic cytokine production in human tumor xenografts. Cytokine 2003;21:98-104.
15. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from antiangiogenic agents in malignancy. Nat Rev Cancer 2006;6:626-35.
16. Cai W, Chen X. Multimodality molecular imaging of tumor angiogenesis. J Nucl Med 2008;49Suppl 2:113S-28S.
17. Jain RK. Lessons from multidisciplinary translational trials on antiangiogenic therapy of cancer. Nat Rev Cancer 2008;8:309-16.
18. O'Connor JP, Carano RA, Clamp AR, Ross J, Ho CC, Jackson A, et al. Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging. Clin Cancer Res 2009;15:6674-82.
19. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009;27:2542-52.
20. Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008;26:4572-8.
21. Perini R, Choe R, Yodh AG, Sehgal C, Divgi CR, Rosen MA, et al. Noninvasive assessment of tumor neovasculature: techniques and clinical applications. Cancer Metastasis Rev 2008;27:615-30.
22. Frangioni JV. New technologies for human cancer imaging. J Clin Oncol 2008;26:4012-21.
23. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201-12.
24. Backer MV, Levashova Z, Patel V, Jehning BT, Claffey K, Blankenberg FE, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med 2007;13:504-9.
25. Stollman TH, Scheer MG, Franssen GM, et al. Tumor accumulation of radiolabeled bevacizumab due to targeting of cell- and matrix-associated VEGF-A isoforms. Cancer Biother Radiopharm 2009;24:195-200.
26. Stein MN, Flaherty KT. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res 2007;13:3765-70.
27. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H, et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009;69:2506-13.
28. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005;24:5552-60.
29. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
30. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61.
31. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
32. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116:2610-21.
33. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26:1810-6.
34. Desar IM, Mulder SF, Stillebroer AB, van Spronsen DJ, van der Graaf WT, Mulders PF, et al. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol 20091-4.
35. Saleem A, Price PM. Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure. Clin Cancer Res 2008;14:8184-90.
36. Anderson H, Yap JT, Wells P, Miller MP, Propper D, Price P, et al. Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer 2003;89:262-7.
37. Nagengast W.B., Lub-De Hooge M.N., Hospers G.A., Brouwers A.H., Hoekstra H.J., Elsinga P.H., et al. Towards clinical VEGF imaging using the anti-VEGF antibody bevacizumab and Fab-fragment ranibizumab. In: Proc Am Soc Clin Oncology Ann. Meeting 2008-3547.
38. Clinical Trial Registration Database. Available from: www.clinicaltrials. gov. Registration number NCT00831857